Skip to main content
Journal cover image

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

Publication ,  Journal Article
Bajorin, DF; Halabi, S; Small, E
Published in: Clin Genitourin Cancer
October 2009

BACKGROUND: Arsenic trioxide is highly active in patients with acute promyelocytic leukemia. There are also preclinical data to suggest that this drug might be active in nonhematopoietic malignancies, and transitional cell carcinoma cell lines are particularly sensitive to this agent. PATIENTS AND METHODS: Twelve evaluable patients with metastatic urothelial cancer were treated with arsenic trioxide in a phase II trial conducted by the Cancer and Leukemia Group B. Eligible patients were required to have measurable urothelial cancer and a maximum of 1 previous chemotherapy regimen. Arsenic trioxide was given at a dose of 0.3 mg/kg daily for 5 days every 28 days. RESULTS: No major responses were observed; 4 patients achieved stable disease. The median survival was 6.5 months (95% CI, 3.9-13.4 months). The most commonly observed toxicities included fatigue and malaise, anemia, nausea, emesis, and constipation. CONCLUSION: Arsenic trioxide at this dose and schedule does not have significant activity in previously treated urothelial cancer and has substantial toxicity in this patient population.

Duke Scholars

Published In

Clin Genitourin Cancer

DOI

EISSN

1938-0682

Publication Date

October 2009

Volume

7

Issue

3

Start / End Page

E66 / E70

Location

United States

Related Subject Headings

  • Urothelium
  • Urologic Neoplasms
  • Urinary Bladder Neoplasms
  • Treatment Outcome
  • Survival Analysis
  • Recurrence
  • Oxides
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bajorin, D. F., Halabi, S., & Small, E. (2009). Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clin Genitourin Cancer, 7(3), E66–E70. https://doi.org/10.3816/CGC.2009.n.026
Bajorin, Dean F., Susan Halabi, and Eric Small. “Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).Clin Genitourin Cancer 7, no. 3 (October 2009): E66–70. https://doi.org/10.3816/CGC.2009.n.026.
Bajorin DF, Halabi S, Small E. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clin Genitourin Cancer. 2009 Oct;7(3):E66–70.
Bajorin, Dean F., et al. “Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).Clin Genitourin Cancer, vol. 7, no. 3, Oct. 2009, pp. E66–70. Pubmed, doi:10.3816/CGC.2009.n.026.
Bajorin DF, Halabi S, Small E. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clin Genitourin Cancer. 2009 Oct;7(3):E66–E70.
Journal cover image

Published In

Clin Genitourin Cancer

DOI

EISSN

1938-0682

Publication Date

October 2009

Volume

7

Issue

3

Start / End Page

E66 / E70

Location

United States

Related Subject Headings

  • Urothelium
  • Urologic Neoplasms
  • Urinary Bladder Neoplasms
  • Treatment Outcome
  • Survival Analysis
  • Recurrence
  • Oxides
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male